Obviously, RPL10 showed a positive correlation with modifier UFM1 and E3 ligase UFL1 and a negative correlation with UFSP2 in PAAD patients (Fig. 1E). This evidence concerns the gene UFM1 and pancreatic adenocarcinoma.